Cargando…

A Cell-Targeted, Size-Photocontrollable, Nuclear-Uptake Nanodrug Delivery System for Drug-Resistant Cancer Therapy

[Image: see text] The development of multidrug resistance (MDR) has become an increasingly serious problem in cancer therapy. The cell-membrane overexpression of P-glycoprotein (P-gp), which can actively efflux various anticancer drugs from the cell, is a major mechanism of MDR. Nuclear-uptake nanod...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Liping, Chen, Tao, Öçsoy, Ismail, Yasun, Emir, Wu, Cuichen, Zhu, Guizhi, You, Mingxu, Han, Da, Jiang, Jianhui, Yu, Ruqin, Tan, Weihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296921/
https://www.ncbi.nlm.nih.gov/pubmed/25479133
http://dx.doi.org/10.1021/nl503777s
_version_ 1782353065347645440
author Qiu, Liping
Chen, Tao
Öçsoy, Ismail
Yasun, Emir
Wu, Cuichen
Zhu, Guizhi
You, Mingxu
Han, Da
Jiang, Jianhui
Yu, Ruqin
Tan, Weihong
author_facet Qiu, Liping
Chen, Tao
Öçsoy, Ismail
Yasun, Emir
Wu, Cuichen
Zhu, Guizhi
You, Mingxu
Han, Da
Jiang, Jianhui
Yu, Ruqin
Tan, Weihong
author_sort Qiu, Liping
collection PubMed
description [Image: see text] The development of multidrug resistance (MDR) has become an increasingly serious problem in cancer therapy. The cell-membrane overexpression of P-glycoprotein (P-gp), which can actively efflux various anticancer drugs from the cell, is a major mechanism of MDR. Nuclear-uptake nanodrug delivery systems, which enable intranuclear release of anticancer drugs, are expected to address this challenge by bypassing P-gp. However, before entering the nucleus, the nanocarrier must pass through the cell membrane, necessitating coordination between intracellular and intranuclear delivery. To accommodate this requirement, we have used DNA self-assembly to develop a nuclear-uptake nanodrug system carried by a cell-targeted near-infrared (NIR)-responsive nanotruck for drug-resistant cancer therapy. Via DNA hybridization, small drug-loaded gold nanoparticles (termed nanodrugs) can self-assemble onto the side face of a silver–gold nanorod (NR, termed nanotruck) whose end faces were modified with a cell type-specific internalizing aptamer. By using this size-photocontrollable nanodrug delivery system, anticancer drugs can be efficiently accumulated in the nuclei to effectively kill the cancer cells.
format Online
Article
Text
id pubmed-4296921
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-42969212015-12-05 A Cell-Targeted, Size-Photocontrollable, Nuclear-Uptake Nanodrug Delivery System for Drug-Resistant Cancer Therapy Qiu, Liping Chen, Tao Öçsoy, Ismail Yasun, Emir Wu, Cuichen Zhu, Guizhi You, Mingxu Han, Da Jiang, Jianhui Yu, Ruqin Tan, Weihong Nano Lett [Image: see text] The development of multidrug resistance (MDR) has become an increasingly serious problem in cancer therapy. The cell-membrane overexpression of P-glycoprotein (P-gp), which can actively efflux various anticancer drugs from the cell, is a major mechanism of MDR. Nuclear-uptake nanodrug delivery systems, which enable intranuclear release of anticancer drugs, are expected to address this challenge by bypassing P-gp. However, before entering the nucleus, the nanocarrier must pass through the cell membrane, necessitating coordination between intracellular and intranuclear delivery. To accommodate this requirement, we have used DNA self-assembly to develop a nuclear-uptake nanodrug system carried by a cell-targeted near-infrared (NIR)-responsive nanotruck for drug-resistant cancer therapy. Via DNA hybridization, small drug-loaded gold nanoparticles (termed nanodrugs) can self-assemble onto the side face of a silver–gold nanorod (NR, termed nanotruck) whose end faces were modified with a cell type-specific internalizing aptamer. By using this size-photocontrollable nanodrug delivery system, anticancer drugs can be efficiently accumulated in the nuclei to effectively kill the cancer cells. American Chemical Society 2014-12-05 2015-01-14 /pmc/articles/PMC4296921/ /pubmed/25479133 http://dx.doi.org/10.1021/nl503777s Text en Copyright © 2014 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Qiu, Liping
Chen, Tao
Öçsoy, Ismail
Yasun, Emir
Wu, Cuichen
Zhu, Guizhi
You, Mingxu
Han, Da
Jiang, Jianhui
Yu, Ruqin
Tan, Weihong
A Cell-Targeted, Size-Photocontrollable, Nuclear-Uptake Nanodrug Delivery System for Drug-Resistant Cancer Therapy
title A Cell-Targeted, Size-Photocontrollable, Nuclear-Uptake Nanodrug Delivery System for Drug-Resistant Cancer Therapy
title_full A Cell-Targeted, Size-Photocontrollable, Nuclear-Uptake Nanodrug Delivery System for Drug-Resistant Cancer Therapy
title_fullStr A Cell-Targeted, Size-Photocontrollable, Nuclear-Uptake Nanodrug Delivery System for Drug-Resistant Cancer Therapy
title_full_unstemmed A Cell-Targeted, Size-Photocontrollable, Nuclear-Uptake Nanodrug Delivery System for Drug-Resistant Cancer Therapy
title_short A Cell-Targeted, Size-Photocontrollable, Nuclear-Uptake Nanodrug Delivery System for Drug-Resistant Cancer Therapy
title_sort cell-targeted, size-photocontrollable, nuclear-uptake nanodrug delivery system for drug-resistant cancer therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296921/
https://www.ncbi.nlm.nih.gov/pubmed/25479133
http://dx.doi.org/10.1021/nl503777s
work_keys_str_mv AT qiuliping acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT chentao acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT ocsoyismail acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT yasunemir acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT wucuichen acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT zhuguizhi acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT youmingxu acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT handa acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT jiangjianhui acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT yuruqin acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT tanweihong acelltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT qiuliping celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT chentao celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT ocsoyismail celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT yasunemir celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT wucuichen celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT zhuguizhi celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT youmingxu celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT handa celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT jiangjianhui celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT yuruqin celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy
AT tanweihong celltargetedsizephotocontrollablenuclearuptakenanodrugdeliverysystemfordrugresistantcancertherapy